更正：丰加霉素可减轻游离脂肪酸诱导的培养肝细胞中的肝脂肪变性和细胞凋亡，并改善小鼠非酒精性脂肪性肝病。
Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
作者信息
Takahara Ikuko, Akazawa Yuko, Tabuchi Maiko, Matsuda Katsuya, Miyaaki Hisamitsu, Kido Youko, Kanda Yasuko, Taura Naota, Ohnita Ken, Takeshima Fuminao, Sakai Yusuke, Eguchi Susumu, Nakashima Masahiro, Nakao Kazuhiko
出版信息
PLoS One. 2020 Jul 1;15(7):e0235729. doi: 10.1371/journal.pone.0235729. eCollection 2020.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0170591.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0170591。]
相似文献
1
Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.更正：丰加霉素可减轻游离脂肪酸诱导的培养肝细胞中的肝脂肪变性和细胞凋亡，并改善小鼠非酒精性脂肪性肝病。
PLoS One. 2020 Jul 1;15(7):e0235729. doi: 10.1371/journal.pone.0235729. eCollection 2020.
2
Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.丰加霉素可减轻游离脂肪酸诱导的培养肝细胞中的肝脂肪变性和细胞凋亡，并改善小鼠的非酒精性脂肪性肝病。
PLoS One. 2017 Mar 9;12(3):e0170591. doi: 10.1371/journal.pone.0170591. eCollection 2017.
3
Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice.抑制可溶性环氧化物水解酶通过增强脂肪酸的β氧化改善高同型半胱氨酸血症诱导的小鼠肝脂肪变性。
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G527-G538. doi: 10.1152/ajpgi.00148.2018. Epub 2019 Feb 21.
4
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro.牛磺酸通过抑制非酒精性脂肪性肝病模型体内和体外的氧化应激来减轻肝脂肪变性的发展。
Amino Acids. 2018 Sep;50(9):1279-1288. doi: 10.1007/s00726-018-2605-8. Epub 2018 Jun 26.
5
Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.原花青素 B2 通过调节 TFEB 介导线粒体途径和氧化还原状态改善游离脂肪酸诱导的肝脂肪变性。
Free Radic Biol Med. 2018 Oct;126:269-286. doi: 10.1016/j.freeradbiomed.2018.08.024. Epub 2018 Aug 22.
6
Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.鞣花酸通过抑制 AKT/SREBP-1/FASN 通路的从头脂生成来改善 AKT 驱动的小鼠肝脂肪变性。
Food Funct. 2019 Jun 19;10(6):3410-3420. doi: 10.1039/c9fo00284g.
7
Correction: The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and Monkeys.更正：脂肪酸合酶抑制剂普拉他汀在小鼠和猴子中可改善胰岛素抵抗且不会诱发肝脂肪变性
PLoS One. 2017 Jan 19;12(1):e0170721. doi: 10.1371/journal.pone.0170721. eCollection 2017.
8
Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.肝细胞特异性破坏CD36可减轻高脂饮食喂养小鼠的脂肪肝并改善胰岛素敏感性。
Endocrinology. 2016 Feb;157(2):570-85. doi: 10.1210/en.2015-1866. Epub 2015 Dec 9.
9
A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.内质网应激诱导脂肪变性建立的人诱导多能干细胞源性肝细胞非酒精性脂肪性肝病模型。
Dis Model Mech. 2018 Sep 25;11(9):dmm033530. doi: 10.1242/dmm.033530.
10
Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein.乙型肝炎病毒X蛋白通过增强肝脏脂肪酸结合蛋白的表达诱导肝脂肪变性。
J Virol. 2015 Dec 4;90(4):1729-40. doi: 10.1128/JVI.02604-15. Print 2016 Feb 15.
本文引用的文献
1
Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.丰加霉素可减轻游离脂肪酸诱导的培养肝细胞中的肝脂肪变性和细胞凋亡，并改善小鼠的非酒精性脂肪性肝病。
PLoS One. 2017 Mar 9;12(3):e0170591. doi: 10.1371/journal.pone.0170591. eCollection 2017.
Zotero 插件